Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate worth approximately Rs.825 crore (USD 91 million) from a leading global pharmaceutical major. With this milestone deal, the company formally strengthens its presence in the fast-growing CDMO segment.
The company expects supplies under this mandate to begin within the next four to five months. Execution will continue through Q1 of the following financial year, subject to standard operational and regulatory approvals.
One of the Largest CDMO Wins in Company History
Notably, this agreement stands among the most significant single CDMO mandates in Morepen’s history. Through this engagement, the company expands its global manufacturing footprint and reinforces its strategic shift toward structured, long-term supply partnerships.
Strengthening Long-Term Global Manufacturing Programs
Built on more than four decades of active pharmaceutical ingredient (API) manufacturing expertise, Morepen has consistently strengthened its regulatory credibility and global compliance standards. As a result, its CDMO platform now enables deeper collaboration with global pharmaceutical innovators through structured, multi-year supply programs.
Moreover, the mandate highlights the company’s growing capabilities in regulated markets. Morepen operates internationally accredited facilities approved by USFDA, WHO-GMP, and EU regulatory authorities. With fully integrated development-to-commercial manufacturing capabilities, the company efficiently supports complex scale-ups and long-duration supply frameworks.
Simultaneously, Morepen continues to evaluate capacity expansion and technology investments to align with its expanding CDMO opportunity pipeline.
Leadership Commentary on Strategic Growth
As per the press release, Mr. Sushil Suri, Chairman & Managing Director, emphasized the strategic significance of the mandate. He stated that the deal marks an important milestone in the evolution of Morepen’s manufacturing platform. He further noted that global customers’ confidence reflects the company’s strong quality systems, regulatory track record, and execution capabilities. Over the years, Morepen has systematically strengthened its infrastructure and compliance depth, enabling participation in larger and longer-duration global programs.
Adding to this, Mr. Kushal Suri, President – International Growth (API), highlighted that the mandate demonstrates the company’s ability to qualify, execute, and deliver under regulated-market expectations. He explained that the team managed the program end-to-end, covering technical, regulatory, and commercial scale-up. Consequently, the company delivered a solution designed for quality, continuity, and scalability. He also emphasized that this achievement validates Morepen’s credibility and positions the company to convert similar opportunities into larger, multi-year global engagements.
Positioned for Evolving Global Pharma Demand
Importantly, global pharmaceutical companies are increasingly consolidating their supplier networks. They now prefer compliant, scalable, and reliable manufacturing partners capable of ensuring long-term supply continuity. In this evolving landscape, Morepen’s vertically integrated API capabilities, regulatory compliance record, and operational scale strategically position the company to capture growing global CDMO demand.